Amphastar Pharmaceuticals (AMPH) Revenue (2016 - 2025)
Historic Revenue for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $191.8 million.
- Amphastar Pharmaceuticals' Revenue rose 32.74% to $191.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $723.3 million, marking a year-over-year decrease of 3.37%. This contributed to the annual value of $732.0 million for FY2024, which is 1358.98% up from last year.
- Amphastar Pharmaceuticals' Revenue amounted to $191.8 million in Q3 2025, which was up 32.74% from $174.4 million recorded in Q2 2025.
- In the past 5 years, Amphastar Pharmaceuticals' Revenue registered a high of $191.8 million during Q3 2025, and its lowest value of $101.7 million during Q2 2021.
- For the 5-year period, Amphastar Pharmaceuticals' Revenue averaged around $150.0 million, with its median value being $145.7 million (2023).
- As far as peak fluctuations go, Amphastar Pharmaceuticals' Revenue skyrocketed by 5030.18% in 2023, and later crashed by 437.51% in 2025.
- Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Revenue stood at $120.9 million in 2021, then grew by 11.69% to $135.0 million in 2022, then skyrocketed by 31.91% to $178.1 million in 2023, then increased by 4.73% to $186.5 million in 2024, then rose by 2.85% to $191.8 million in 2025.
- Its Revenue stands at $191.8 million for Q3 2025, versus $174.4 million for Q2 2025 and $170.5 million for Q1 2025.